Checkpoint Therapeutics – Consensus Indicates Potential 582.7% Upside

Broker Ratings

Checkpoint Therapeutics with ticker code (CKPT) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 20 and 17 with a mean TP of 18.5. Given that the stocks previous close was at 2.71 this now indicates there is a potential upside of 582.7%. There is a 50 day moving average of 2.62 and the 200 moving average now moves to 2.47. The market cap for the company is $216m. Find out more information at:

Checkpoint Therapeutics, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics has collaboration agreements with TG Therapeutics to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics is a subsidiary of Fortress Biotech

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index